Strategic Supply Agreement for Terbium-161
In a significant move for the radiopharmaceutical industry, ITM Isotope Technologies Munich SE (ITM) and TerThera BV have signed a pivotal supply agreement for non-carrier-added (n.c.a.) Terbium-161 (Tb-161). This partnership aims to harness the potential of Tb-161, a novel medical radioisotope, in the development of advanced cancer therapies.
Enhancing Radiopharmaceutical Therapies
As the fields of oncology and radiopharmaceuticals evolve, the demand for effective treatment options grows. ITM, a prominent player in the biotech landscape, is focused on delivering cutting-edge innovations to clinicians and patients. With the supply agreement with TerThera, ITM can further enhance its pipeline of Tb-161-based therapies, which are currently under clinical investigation for various cancer types.
Why Terbium-161?
Terbium-161 presents a unique profile in terms of its emission characteristics. Similar to Lu-177, it emits medium-range beta particles and shares a comparable half-life. However, what sets Tb-161 apart is its additional emissions of low-energy Auger and internal conversion electrons. This capability allows for highly localized radiation that targets isolated cancer cells and micro-metastases with reduced collateral damage to healthy tissues.
Statements from Leadership
Dr. Andrew Cavey, CEO of ITM, emphasized the significance of this collaboration, stating, "Driving innovation across isotopes, targeting molecules, and cancer indications keeps ITM at the forefront of the rapidly evolving radiopharmaceutical industry. We see strong potential in Terbium-161 as a critical new isotope for targeted therapy, allowing us to make meaningful advances for patients living with cancer."
Commitment to Quality and Safety
Under the terms of the newly minted agreement, TerThera is tasked with delivering GMP-compliant Tb-161 to ITM. Philippe van Overeem, CEO of TerThera, noted, "As the industry interest in Terbium-161 grows, a secure and sustainable supply of this radionuclide is essential. ITM stands as a true innovator in the radiopharmaceutical field, and we look forward to collaborating with them to bring this promising isotope to patients in need." This commitment ensures that the treatments developed in this partnership will meet the highest standards of quality and safety.
Transforming Cancer Treatment
The implications of this agreement extend beyond mere supply logistics. By incorporating Tb-161 into their therapy development, ITM aims to leverage the unique properties of this isotope to unlock new avenues for treating patients with hard-to-treat tumors. The company’s ongoing precision oncology initiatives include multiple Phase 3 studies, demonstrating a robust effort to utilize high-quality radioisotopes combined with innovative targeting molecules.
Future Prospects
With a dedication to improving clinical outcomes, ITM is on a mission to enhance the quality of life for cancer patients worldwide. The collaboration with TerThera will add a compelling component to their offering, supporting the advancement of targeted radiopharmaceutical treatments. As ITM builds upon its established global network and two decades of expertise, the partnership is poised to contribute significantly to the future of oncological therapies.
About ITM and TerThera
ITM is committed to delivering innovative radiopharmaceutical therapeutics and diagnostics, focusing on the unmet needs of cancer patients and their treatment. By emphasizing excellence in the development, production, and global supply of medical radioisotopes, ITM remains at the forefront of precision oncology.
TerThera, based in the Netherlands, is a dedicated player in radionuclide production. With decades of experience in nuclear medicine, the team is focused on making their innovative Terbium-161 available for clinical use. Their ongoing efforts to establish GMP production facilities in Europe, the USA, and Asia highlight the company’s commitment to meeting global radionuclide demands.
Frequently Asked Questions
What is the purpose of the agreement between ITM and TerThera?
The agreement focuses on supplying non-carrier-added Terbium-161 to support ITM’s development of advanced radiopharmaceutical therapies for cancer.
What are the benefits of Terbium-161 in cancer treatment?
Terbium-161 offers unique emissions that allow for targeted radiation to cancer cells, minimizing damage to surrounding healthy tissues.
Who are the key figures mentioned in the agreement?
Dr. Andrew Cavey, CEO of ITM, and Philippe van Overeem, CEO of TerThera, are two notable leaders involved in this initiative.
How does ITM intend to utilize the Tb-161 isotope?
ITM plans to incorporate Tb-161 into its pipeline of cancer therapies, which are currently in various stages of clinical trials.
What is the overall mission of ITM and TerThera?
Both companies share a commitment to innovation in radiopharmaceuticals, aiming to enhance patient outcomes and quality of life through advanced treatments.
